Quantifying Abnormalities in Cortical Activation Associated With Auditory Hallucinations Using Functional Magnetic Resonance Imaging
2 other identifiers
interventional
60
1 country
1
Brief Summary
The goal of the project is to characterize abnormalities in brain structure and function related to schizophrenia. The investigators will use advanced magnetic resonance imaging (MRI) techniques to measure the degree and distribution of neuronal activity during specific cognitive tasks, alterations in neuronal connectivity, and how these are related to disease symptoms and treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable schizophrenia
Started Jan 2006
Shorter than P25 for not_applicable schizophrenia
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2006
CompletedFirst Submitted
Initial submission to the registry
February 6, 2006
CompletedFirst Posted
Study publicly available on registry
February 7, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2006
CompletedApril 19, 2017
April 1, 2017
7 months
February 6, 2006
April 17, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
characterize abnormalities in brain structure and function related to schizophrenia
two scans over a six month period
Study Arms (1)
1,2
ACTIVE COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Investigators will study subjects who:
- Are between the ages of 18 and 65.
- Meet diagnostic criteria for any psychiatric disorder with auditory hallucinations (at least one every 20 minutes) including schizophrenia/schizoaffective disorder OR schizophrenia/schizoaffective disorder without auditory hallucinations.
- Have been treated with an antipsychotic drug for hallucinations at least three months or are unmedicated
- Are willing to change their current antipsychotic medication if indicated
- Are able to provide written consent
- Normal controls must :
- Be between the ages of 18 and 65
- Not meet the diagnostic criteria for schizophrenia or schizoaffective disorder or other psychiatric disorder involving hallucinations
- Not currently be treated with an antipsychotic drug
- Be able to provide written consent
You may not qualify if:
- Subjects and normal controls will be excluded from participation if there is:
- Evidence of non-psychiatric, chronic central nervous system (CNS) disease (such as brain injury or neurological disease)
- Contraindication to MRI, including prior claustrophobic reaction and severe movement disorder
- A recent change in menstrual status other than recent changes in oral or implanted contraceptive use (for females)
- A positive pregnancy result (for females)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adam Anderson, Ph.D.
Vanderbilt University Medical Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 6, 2006
First Posted
February 7, 2006
Study Start
January 1, 2006
Primary Completion
August 1, 2006
Study Completion
August 1, 2006
Last Updated
April 19, 2017
Record last verified: 2017-04